Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.031 AUD | +6.90% | +10.71% | +29.17% |
08/04 | AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market | MT |
26/02 | AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 2.75M 1.8M 150M | Sales 2023 | 3.47M 2.27M 189M | Capitalization | 8.8M 5.75M 479M |
---|---|---|---|---|---|
Net income 2022 | -6M -3.92M -327M | Net income 2023 | -4M -2.61M -218M | EV / Sales 2022 | 4.47 x |
Net cash position 2022 | 4.66M 3.04M 254M | Net cash position 2023 | 776K 507K 42.24M | EV / Sales 2023 | 2.31 x |
P/E ratio 2022 |
-2.48
x | P/E ratio 2023 |
-1.57
x | Employees | 10 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 63.48% |
1 day | +6.90% | ||
1 week | +10.71% | ||
Current month | +14.81% | ||
1 month | +24.00% | ||
3 months | +34.78% | ||
6 months | +40.91% | ||
Current year | +29.17% |
Managers | Title | Age | Since |
---|---|---|---|
Timothy Oldham
CEO | Chief Executive Officer | - | 14/19/14 |
Mick Foley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dallas Hartman
COO | Chief Operating Officer | - | 09/17/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Peach
BRD | Director/Board Member | 68 | 14/16/14 |
Paul MacLeman
CHM | Chairman | 58 | 16/15/16 |
Timothy Oldham
CEO | Chief Executive Officer | - | 14/19/14 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.031 | +6.90% | 318,998 |
24/24/24 | 0.029 | 0.00% | 344,254 |
23/24/23 | 0.029 | +3.57% | 116,689 |
22/24/22 | 0.028 | 0.00% | 957,491 |
19/24/19 | 0.028 | +3.70% | 2,964,789 |
Delayed Quote Australian S.E., April 26, 2024 at 08:30 am IST
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+29.17% | 10.63M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 1AD Stock